Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
Advances in Experimental Medicine and Biology|June 3, 2020
Using Liquid Biopsy in the Treatment of Patient with OSDavid S Shulman, Brian D CromptonPaediatric Drugs|January 23, 2020
The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric CancersDavid S Shulman, Steven G DuBoisHematology/Oncology Clinics of North America|May 23, 2025
Emerging Role of Blood-based Biomarkers in SarcomasDavid S Shulman, Brian D CromptonPediatric Blood & Cancer|July 27, 2019
Second malignancies in patients treated for Ewing sarcoma: A systematic reviewJennifer Caruso, David S Shulman, Steven G DuBoisEuropean Journal of Cancer (Oxford, England : 1990)|April 1, 2019
Timing of first-in-child trials of FDA-approved oncology drugsDylan V Neel, David S Shulman, Steven G DuBoisPediatric Blood & Cancer|January 8, 2019
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsiesSamuel D Abbou, David S Shulman, Steven G DuBois, et al.Journal of Pediatric Hematology/Oncology|July 13, 2016
Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase InhibitorsDavid S Shulman, Michelle A Lee, Leslie E Lehmann, et al.Pediatric Blood & Cancer|November 21, 2020
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic reviewKevin M Campbell, David S Shulman, Holcombe E Grier, et al.Cancer Medicine|May 1, 2020
Sponsorship of oncology clinical trials in the United States according to age of eligibilityDylan V Neel, David S Shulman, Clement Ma, et al.JCO Precision Oncology|December 23, 2024
Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted TherapiesClement Ma, David S Shulman, Hasan Al-Sayegh, et al.Pageof 6